Where does Array BioPharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Array BioPharma, Inc. ranks #2,071 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Array BioPharma, Inc. hold?

Array BioPharma, Inc. holds 191 US utility patents granted between 2015 and 2025, spanning 14 technology areas.

What is Array BioPharma, Inc.'s Innovation Score?

Array BioPharma, Inc. has an Innovation Score of 48.9 out of 100 (top 16% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Array BioPharma, Inc. focus on?

Array BioPharma, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 183 patents, ranking #74 of 6,058 assignees active in that subclass. Grants appear in 14 CPC subclasses total.

Is Array BioPharma, Inc.'s patent grant rate increasing or decreasing?

Array BioPharma, Inc.'s recent grant velocity is -44% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Array BioPharma, Inc.'s patents?

Array BioPharma, Inc.'s patents average 23.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Array BioPharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Array BioPharma, Inc.

USPTO PatentsView assignee record - 191 granted patents across 14 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Array ranks #2,071 of 49,997 tracked US assignees by granted-patent volume, with 191 patents across 14 technology areas.

#2,071
of 49,997 US assignees by volume: Top 16%
by Innovation Score (48.9/100): 23.8
avg claims per patent: -44%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2071 · US Corporation #2,071 · 191 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 191 grants
TOP-DECILE #2,071/49,997
PHOTO-FINISH Isco International
CPC-FOCUS A61P · 14 areas
INNOV-PAR 48.9/100
CLAIMS-DENSE 23.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -44% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Isco International, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Array’s 48.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 18.2 pts (37%) Velocity 3.3 pts (7%) Breadth 13.2 pts (27%) Claim depth 14.3 pts (29%)

Qualcomm Incorporated · highest

85
Alpha · near

49
Array BioPharma · this assignee

49
Cool Planet Energy… · near

49
Gravic · near

49
T-max (HANGZHOU)… · near

49
3D Lighting… · lowest

7

What this shows Array's Innovation Score is 48.9/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Array?

Each dot is one of Array’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Array’s own 23.8 claims/patent is ABOVE the 12.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Array vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Array's grants concentrate

Array BioPharma, Inc. is a focused PatentsView assignee: 14 CPC subclasses with 95.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (38 grants) versus a trough of 7 in 2024. By volume, Array sits between Safran Helicopter Engines and Stolle Machinery Company, LLC.

Array's three-year grant acceleration

From 2019–2021 to 2022–2024, Array BioPharma, Inc. moved from 59 to 29 grants (0.49x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,710. See the growth leaderboard.

Safran Helicopter…

192
Sagemcom Broadban…

192
Saint-gobain Abra…

192
Zhejiang Sunny Op…

192
Isco International

191
Nortonlifelock

191
Sanken Electric

191
Stolle Machinery

191
Array Biopharma ◀

191

What this shows Array holds 191 patents at rank #2,071, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Array

By rank, the assignees closest to #2,071 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Array's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Array, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Array ranks #74 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (49 here).

Alpha Corporation 49 Gravic, Inc. 49 T-max (HANGZHOU) Technology, Co., Ltd. 49 Cool Planet Energy System, Inc. 49

Similar claim depth

Nearest assignees by average claims per patent (23.8 here).

Koninklijke Douwe Egberts B.V. 23.8 avg KLA Corporation 23.8 avg Hollingsworth & Vose Company 23.8 avg Haemonetics Corporation 23.8 avg

Array's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Array BioPharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	18	9.4%
2016	21	11.0%
2017	38	19.9%
2018	21	11.0%
2019	21	11.0%
2020	26	13.6%
2021	12	6.3%
2022	10	5.2%
2023	12	6.3%
2024	7	3.7%
2025partial year	5	2.6%

Which technologies does Array BioPharma, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 183

C07D - Heterocyclic Compounds 169

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 124

Y02A - Technologies FOR Adaptation TO Climate Change 36

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 14

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 13

C07C - Acyclic OR Carbocyclic Compounds 11

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 8

C30B - Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrystalline Material With Defined Structure ; Single Crystals OR Homogeneous Polycrystalline Material WI 7

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 5

C12Y - Enzymes 5

C04B - Lime, MAGNESIA; SLAG; CEMENTS; Compositions Thereof, e.g. Mortars, Concrete OR Like Building MATERIALS; Artificial Stone ; Ceramics ; REFRACTORIES; Treatment OF Natural Stone 3

C07K - Peptides 2

Top 14 of 14 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Array BioPharma, Inc.'s patent record in context - here's where to go next.

Array BioPharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 95.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,071 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Array BioPharma, Inc. against Safran Helicopter Engines, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.